The Medicines and Healthcare products Regulatory Agency (MHRA) has forced Eli Lilly to withdraw an advice leaflet. The leaflet, providing doctors with advice on treatments for mental health, was written on behalf of Diabetes UK and carried the logo of the charity, reports the Financial Times.

However, Eli Lilly admitted that it omitted to include that it had sponsored the leaflet, calling the mistake an oversight. The firm was also criticised for not making the risk of schizophrenia medicines clear, including its own drug Zyprexa (olanzapine), to people suffering from hyperglycaemia and diabetes. The MHRA has called for Eli Lilly to withdraw the information, originally distributed in 2003, although it was removed in May last year by the firm.